CJC-1295 DAC

CJC-1295 DAC (also written DAC-GRF) is a synthetic 30-amino-acid growth hormone-releasing hormone (GHRH) analog incorporating a Drug Affinity Complex (DAC) — a trans-4-aminomethylcyclohexane carboxylic acid group — that enables covalent binding to circulating albumin. This albumin binding is the defining feature of the DAC variant: it extends the plasma half-life from the minutes characteristic of native GHRH and short-acting analogs to approximately 6–8 days, and is the pharmacological basis for the less-frequent administration schedules described in the research literature.

GH and IGF-1 elevation studied in a single-dose human PK trial, sustained GHRH-receptor agonism via albumin binding, extended plasma half-life relative to short-acting GHRH analogs, body-composition and GH-axis research contexts, subcutaneous administration in published research.

Research on CJC-1295 DAC primarily documents effects related to GH and IGF-1 elevation studied in a single-dose human PK trial and sustained GHRH-receptor agonism via albumin binding and extended plasma half-life relative to short-acting GHRH analogs and body-composition and GH-axis research contexts and subcutaneous administration in published research. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for CJC-1295 DAC include cardiovascular condition. This is educational information only — consult a qualified healthcare professional before use.

For CJC-1295 DAC, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Across 25 research vendors tracked on PeptideBase, CJC-1295 DAC has a median price of about $11.99 per mg, typically ranging $8.40–$15.80 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

Research in two randomized controlled trials found that a single injection of CJC-1295 produced 2- to 10-fold increases in serum growth hormone and 1.5- to 3-fold increases in IGF-1 concentrations sustained for 6 or more days, with an acceptable safety and tolerability profile in healthy adults.